A new article from Fox Chase Cancer Center, covered by Onclive, explores how home-based monitoring may change the landscape of T-cell redirecting therapies. While the detailed content remains behind a paywall, its premise highlights the possibility of more personalized treatment outside traditional settings.

DS-3939, a new therapy candidate, is showing encouraging early-stage results in a Phase 1/2 trial targeting advanced solid tumors. While full details remain behind a paywall, initial findings from a recent announcement suggest possibilities for future cancer treatment options.

Promising advances in immunotherapy may allow some cancer patients to bypass chemotherapy, radiation, and surgery. New clinical trial findings reported by Dr. Jon LaPook suggest a groundbreaking shift in cancer treatment, offering renewed hope to many.